The DOI matches its Crossref record; 49 of the 51 references it cites were found in a registry or an index; 10 of the 34 sources its claims cite were checked for support.
Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis
Open accessAbstract
Due to their bacterial ancestry, many components of mitochondria share structural similarities with bacteria. Release of molecular danger signals from injured cell mitochondria (mitochondria-derived damage-associated molecular patterns, mito-DAMPs) triggers a potent inflammatory response, but their role in fibrosis is unknown. Using liver fibrosis resistant/susceptible mouse strain system, we demonstrate that mito-DAMPs released from injured hepatocyte mitochondria (with mtDNA as major active component) directly activate hepatic stellate cells, the fibrogenic cell in the liver, and drive liver scarring. The release of mito-DAMPs is controlled by efferocytosis of dying hepatocytes by phagocytic resident liver macrophages and infiltrating Gr-1(+) myeloid cells. Circulating mito-DAMPs are markedly increased in human patients with non-alcoholic steatohepatitis (NASH) and significant liver fibrosis. Our study identifies specific pathway driving liver fibrosis, with important diagnostic and therapeutic implications. Targeting mito-DAMP release from hepatocytes and/or modulating the phagocytic function of macrophages represents a promising antifibrotic strategy.
Overview
CoChat Summary
## TL;DR
This study shows that inefficient clearance of dying hepatocytes allows mitochondria-derived danger signals, especially mtDNA, to escape and directly activate hepatic stellate cells, driving liver fibrosis in mice. In humans, circulating mtDNA was higher in NAFLD/NASH and tracked with active NASH and significant fibrosis.
## Key findings
- In a single-dose TAA injury model, fibrosis severity ranked BALB/c > C57Bl/6 > FVB, with BALB/c showing maximum collagen levels 142% above controls by day 8, versus 77% in FVB and 88% in C57Bl/6.
- Dead hepatocyte clearance was slower in fibrosis-susceptible BALB/c mice: necrotic hepatocytes disappeared by day 3 in FVB but persisted beyond day 5 in BALB/c; apoptotic cell engulfment by macrophages dropped by 43.5% in BALB/c versus 24.7% in FVB after injury.
- Depleting phagocytes erased fibrosis resistance in FVB mice: macrophage depletion made resistant mice “completely susceptible,” and Gr-1 antibody depletion caused persistence of dead hepatocytes and increased hepatic collagen deposition.
- Exogenous mito-DAMPs were profibrotic: in injured FVB mice they caused a 2.5-fold increase in collagen by morphometry and a 27.45% increase in hydroxyproline, and in vitro they induced HSC activation, proliferation, α-SMA, and 2–4-fold increases in pro-fibrogenic genes; DNase treatment reduced this activity by up to 50%.
- In humans, serum mtDNA was increased 7-fold on average in NAFLD patients vs healthy controls, up to 17-fold in some cases, and was higher in active NASH (NAS 4–8 vs 0–3, p = 0.0334) and in significant fibrosis (F2–4 vs F0–1, p = 0.0003).
## Methods
- Mouse experiments used male inbred strains (FVB/NJ, C57BL/6J, BALB/c) with chronic or single-dose TAA injury; selected experiments also used CCl4 and an MCD diet model.
- Phagocytosis and fibrosis were assessed using clodronate liposomes, Gr-1/CD11b/Ly-6G antibodies, in vivo apoptotic thymocyte uptake assays, qPCR/phagocytosis gene arrays, histology, Sirius Red/α-SMA staining, hydroxyproline, ALT, and in vitro HSC/Kupffer cell assays with purified mito-DAMPs.
- Human data came from 12 healthy controls, a pilot NAFLD cohort (n = 27), and a validation NAFLD/NASH cohort (n = 114); serum mtDNA was quantified by TaqMan PCR and related to biopsy-scored NAS and fibrosis stage.
## Limitations
- The authors state that the extreme fibrosis phenotypes in FVB and BALB/c mice cannot be directly extrapolated to the human population.
- They note that future studies should identify the molecular sensors mediating mtDNA/mito-DAMP effects and further assess the contribution of other mitochondrial components.
- It is evident from the text that much of the mechanistic work is based on mouse models and ex vivo/in vitro assays, so human causality is not directly established (evident from the text).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
9 Valid · 0 Not valid · 17 Not checked · 85 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“This may suggest that pro-fibrogenic role of infiltrating CD11b+ monocytes pool might be indirect and determined by their well-established pro-inflammatory function26.”
§ Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis > Discussion
What the sources say
- Supportedcites [26] Brempelis, K. J. & Crispe, I. N. Infiltrating monocytes in liver injury and repair. Clin. Transl. Immunol. 5, e113 (2016). source
The “Liver injury, sterile inflammation, and fibrosis” section links infiltrating monocytes to inflammatory chemokine production, HSC activation, and fibrosis. The “Monocytes as drivers of fibrosis or resolution of fibrosis?” section explicitly proposes that infiltrating monocytes may activate HSCs, which then initiate fibrosis. Together, these passages support the citing sentence’s hedged suggestion of an indirect, inflammation-related pro-fibrogenic role. (LLM, conf=0.87)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Circulating mito-DAMPs are markedly increased in human patients with non-alcoholic steatohepatitis (NASH) and significant liver fibrosis.”
- Also stated in: § Introduction · plain
“Mitochondrial DNA (mtDNA), a major active component of mito-DAMPs, is elevated in the sera of non-alcoholic steatohepatitis (NASH) patients and particularly those with significant fibrosis.”
§ Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Areas of collagen deposition in livers of mito-DAMP-treated mice overlapped with a massive increase in immunopositivity for α-SMA, an HSC activation marker.”
§ Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis > Results > Hepatocyte-derived mito-DAMPs compromise fibrosis resistance The results described above suggested to us that prolonged exposure to the certain DAMPs released from persisting dead hepatocytes in fibrosis-susceptible strain (or when MΦ function is compromised in resistant FVB mice) may be directly responsible for triggering exaggerated fibrotic responses. One such group of molecules leaking from damaged mitochondria (collectively called mito-DAMPs) is particularly immunogenic and has been implicated in various diseases8. Indeed, we detected transient 3-fold elevation in serum levels of mtDNA (a marker of mito-DAMPs release) 2 days post-TAA injury in fibrosis-susceptible BALB/c mice, but not in resistant FVB mice (Fig. 5a). Importantly, this was not due to strain differences in mtDNA genome copy number, which was similar in FVB and BALB/c livers relative to nuclear genome (Supplementary Fig. 7d, e). To test if mito-DAMPs were directly pro-fibrogenic, we purified liver mitochondria, prepared mito-DAMPs from them, and injected them into resistant FVB mice on the second and fourth day post-TAA injury to mimic prolonged exposure to mito-DAMPs due to inefficient efferocytosis of damaged hepatocyte in vivo (Fig. 5b). The mito-DAMP dose chosen contained 9.5 μg of mtDNA, which corresponds to 10% of the whole liver and in all likelihood reflects pathophysiologic levels based on 40–50% hepatocyte death observed in response to TAA in our system and kinetics of systemic exogenous mito-DAMPs exposure in vivo (Supplementary Fig. 7c). While control FVB mice, as expected, were able to repair the liver injury in a scarless manner by day 8 post injury, FVB mice injected with mito-DAMPs developed significant liver fibrosis, with readily detectable collagen deposits, morphologically characterized as incomplete fibrotic septa (Fig. 5c). Quantitatively, the overall increase in collagen deposition in mice injected with mito-DAMPs was significant, with a 2.5-fold increase as determined via connective tissue square morphometry, and a 27.45% increase as determined via biochemical hydroxyproline assay, respectively (p < 0.05, Fig. 5d, e). Areas of collagen deposition in livers of mito-DAMP-treated mice overlapped with a massive increase in immunopositivity for α-SMA, an HSC activation marker. Moreover, pro-fibrogenic gene transcript levels of TGFβ1, pro-collagen α1(I), and TIMP-1 in livers of mito-DAMP-treated mice remained elevated 3–4-folds at day 8 post injury (Fig. 5f). In order to validate these findings in a second, mechanistically different model of steatohepatitis, we injected mice primed with short-term methionine- and choline-deficient diet (MCD) feeding (2 weeks) with a single dose of purified mito-DAMPs (9.5 μg/mouse, i.p.) and examined the livers 24 h later; in situ immunostaining for α-SMA revealed massive activation of peri-sinusoidal HSCs throughout the liver lobule, with a 2.6-fold increase in α-SMA area morphometrically (Fig. 5g).
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The degree of hepatotoxin-induced injury was similar between all three strains studied, as measured by cumulative serum alanine aminotransferase (ALT) levels 12–96 h post TAA (“area under curve” analysis, Fig. 1c).”
§ Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis > Results > Fibrosis-resistant/-susceptible inbred mouse strain model
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Analysis of apoptotic cell distribution in relation to macrophage markers revealed that liver homing of apoptotic cells, as well as their engulfment rate by F480+-resident macrophages, was significantly lower in injured livers of BALB/c mice compared to FVB (Fig. 3b, c).”
§ Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis > Results > Impaired efferocytosis function in fibrosis-susceptible mice
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
43 more claims
Create a free account to see all 111 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 31
- It may state two separate claims as one. 45
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dying or damaged hepatocytes secrete damage-associated molecular patterns including high mobility group box 1 protein (HMGB1), osteopontin (SPP1), purinoceptor 14 (P2Y14) ligands, apoptotic bodies, microRNA (miRNA), and DNA that can be packaged into microvesicles and directly taken up by HSCs, leading to their activation into collagen-producing myofibroblasts (see “Cellular plasticity”, below) (23”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A previous study on the effect of strain differences in fibrosis susceptibility identified the phagocytic function of macrophages as one determinant of the different outcomes in various mouse strains (40).”
From Stiffness sensing via Piezo1 enhances macrophage efferocytosis and promotes the resolution of liver fibrosis (2024) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“Defective efferocytosis has been linked to fibrotic disorders.”
From Stiffness sensing via Piezo1 enhances macrophage efferocytosis and promotes the resolution of liver fibrosis (2024) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Complementary DNA was prepared from 0.5 mg of RNA using the RT2 first-strand kit and quantitative PCR for 84 phagocytosis-related genes was then performed using the RT2 Profiler mouse phagocytosis PCR array”
§ Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis > Methods > Phagocytosis gene array
Reported 0.5 · recomputed 500
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Circulating mitochondrial DAMPs cause inflammatory responses to injury
Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., Brohi, K., Itagaki, K., & Hauser, C. J. (2010) · Nature · doi:10.1038/nature08780 · Cited by 3,812
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011 · cited 2×
“a Scheme of phagocytic macrophage depletion experiment where single injection of clodronate liposomes was performed either (1) 24 h prior (CLO-TAA) or (2) 24 h after (TAA-CLO) TAA administration, and (3) myeloid cell subsets depletion via administration of Gr-1, CD11b, or Ly-6G-specific mAB on first, third, and fifth…”
BackgroundMethodHepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Resolution of inflammation: the beginning programs the end
Serhan, C. N., & Savill, J. (2005) · Nature Immunology · doi:10.1038/ni1276 · Cited by 2,552
On the origin of mitosing cells
Sagan, L. (1967) · Journal of Theoretical Biology · doi:10.1016/0022-5193(67)90079-3 · Cited by 1,870
Rooijen, N. V., & Sanders, A. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90012-4 · Cited by 1,779
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649
Liver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Macrophages: master regulators of inflammation and fibrosis
Wynn, T., & Barron, L. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255354 · Cited by 1,392
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“It is likely that other lipotoxic mediators underlie the transition from NAFLD to NASH, including mitochondrion-derived danger signals (An et al., 2020) and oxidized phospholipids (Sun et al.”
BackgroundHepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
Oxidative Stress in Liver Pathophysiology and Disease
Allameh, A., Niayesh-Mehr, R., Aliarab, A., Sebastiani, G., & Pantopoulos, K. (2023) · Antioxidants · doi:10.3390/antiox12091653 · Cited by 514
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
“Moreover, mtDNA also directly activates HSCs, driving liver fibrosis progression.(252)”
BackgroundMitochondrial DNA Release in Innate Immune Signaling
Newman, L. E., & Shadel, G. S. (2023) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-032620-104401 · Cited by 318
“Blocking TLR9 signaling pharmacologically prevents the development of NASH (221).”
Background
Metadata
- Authors
- An, P., Wei, L.-L., Zhao, S., Sverdlov, D. Y., Vaid, K. A., Miyamoto, M., Kuramitsu, K., Lai, M., & Popov, Y. V.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Popov, Yury V.
- Venue
- Nature Communications
- Published
- 2020-05-12
- Volume
- 11
- Issue
- 1
- Pages
- 2362-2362
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC7217909
- OpenAlex
- W3024293031
- Semantic Scholar
- 59206e139721dcca344ed60e28544f0ab73567c1
- Cited by
- 319
- References
- 51
- Citations by year
- 2026: 44 · 2025: 53 · 2024: 60 · 2023: 71 · 2022: 51 · 2021: 37 · 2020: 3
- FWCI
- 23.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81302131)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- liver fibrosis, mitochondrial damage-associated molecular patterns, hepatocyte mitochondria, hepatic stellate cells, mitochondrial DNA, efferocytosis, hepatic macrophages, nonalcoholic steatohepatitis, antifibrotic therapy
- MeSH terms
- Alarmins, Adult, Aged, Aged, 80 and over, Animals, Disease Models, Animal, Female, Humans, Liver, Liver Cirrhosis, Macrophages, Male, Middle Aged, Mitochondria, Phagocytosis, Thioacetamide, Apoptosis, Disease Progression, Hepatocytes, Mice, Hepatic Stellate Cells, Young Adult, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis. https://app.cochat.ai/papers/10.1038/s41467-020-16092-0
- The paper
- An, P., Wei, L.-L., Zhao, S., Sverdlov, D. Y., Vaid, K. A., Miyamoto, M., Kuramitsu, K., Lai, M., & Popov, Y. V. (2020). Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis. Nature Communications. https://doi.org/10.1038/s41467-020-16092-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.